{"name":"RasCal Therapeutics, Inc.","slug":"rascal-therapeutics-inc","ticker":"","exchange":"","domain":"rascal.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQcDYtNkd0cHZxTUNOUW5qWEdGRW9UZ1BtTTQxdk90ZFVyRXYyZW00TXJ0RTVVSVlFVUs3T1RaZEVRUnVlOENSRUpjWU9KMnMxS2lPemtLNEVxZnpjbkJIdEhFQVdUN1RGemJHcHJjU3ZWSUVld0E0Q2JOMVM0SmZ5M09pLUoweFdWVFJLMnRsOGNTZ1RrU2xXZlZNX0lZZ1EyWUlrak9TUmF5RVcxUVZ2MDIwSTRwMWkwMzdCeUtMdWc5QldO?oc=5","date":"2025-02-13","type":"pipeline","source":"ascopost.com","summary":"Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer - ascopost.com","headline":"Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOG5sZEpjUzZkYzhvUUl0YVh3QjFuTVdsREQ0SnB0X0trN0NEbmw0Z2ZnZ296dWhQalE1OFNIdHZGYUZ2Q0lIQTQxUElFNWlnbU11dFJWcVQ5Wk12ZWpQaGJyVUZSWnB4NFA0ZXR3TXNIZVNXTFNGb0MtMEl2OC1BaE1NV2xKVnhHM0xJYmpnNVZ5eWUxbDlFczdDaGR3RGV2QlQ0THZkM0RuZ29qZW1kMjcyVGI?oc=5","date":"2024-04-12","type":"pipeline","source":"Seeking Alpha","summary":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD) - Seeking Alpha","headline":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}